{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:17:41Z","timestamp":1762507061132},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/cgt.2017.12","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T10:21:28Z","timestamp":1492770088000},"page":"251-258","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals"],"prefix":"10.1038","volume":"24","author":[{"given":"Q","family":"Ru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"BFcgt201712_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673\u2013682.","journal-title":"Immunity"},{"key":"BFcgt201712_CR2","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687\u201312690.","journal-title":"J Biol Chem"},{"key":"BFcgt201712_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/1535-7163.MCT-13-0645","volume":"13","author":"HZ Wang","year":"2014","unstructured":"Wang HZ, Davis JS, Wu XW . Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity. Mol Cancer Ther 2014; 13: 643\u2013650.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201712_CR4","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","volume":"12","author":"TM Ganten","year":"2006","unstructured":"Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, B\u00fcchler P, Haas TL et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeuticdrugs. Clin Cancer Res 2006; 12: 2640\u20132646.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201712_CR5","doi-asserted-by":"publisher","first-page":"e1035","DOI":"10.1038\/cddis.2013.555","volume":"5","author":"J Trebing","year":"2014","unstructured":"Trebing J, El-Mesery M, Sch\u00e4fer V, Weisenberger D, Siegmund D, Silence K et al. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis 2014; 5: e1035.","journal-title":"Cell Death Dis"},{"key":"BFcgt201712_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbrc.2010.04.134","volume":"396","author":"N M\u00fcller","year":"2010","unstructured":"M\u00fcller N, Schneider B, Pfizenmaier K, Wajant H . Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun 2010; 396: 793\u2013799.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcgt201712_CR7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1535-7163.MCT-09-1076","volume":"9","author":"SY Chae","year":"2010","unstructured":"Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010; 9: 1719\u20131729.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201712_CR8","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1021\/bc200187k","volume":"22","author":"TH Kim","year":"2011","unstructured":"Kim TH, Youn YS, Jiang HH, Lee S, Chen XY, Lee KC . PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjug Chem 2011; 22: 1631\u20131637.","journal-title":"Bioconjug Chem"},{"key":"BFcgt201712_CR9","doi-asserted-by":"publisher","first-page":"e0122980","DOI":"10.1371\/journal.pone.0122980","volume":"10","author":"D Rozanov","year":"2015","unstructured":"Rozanov D, Spellman P, Savinov A, Strongin AY . A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo. PLoS ONE 2015; 10: e0122980.","journal-title":"PLoS ONE"},{"key":"BFcgt201712_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/mt.2016.52","volume":"24","author":"I Gil-Farina","year":"2016","unstructured":"Gil-Farina I, Fronza R, Kaeppel C, Lopez-Franco E, Ferreira V, D'Avola D et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther 2016; 24: 1100\u20131105.","journal-title":"Mol Ther"},{"key":"BFcgt201712_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet 2014; 383: 1129\u20131137.","journal-title":"Lancet"},{"key":"BFcgt201712_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/mt.2016.37","volume":"24","author":"V Pichard","year":"2016","unstructured":"Pichard V, Provost N, Mendes-Madeira A, Libeau L, Hulin P, Tshilenge KT et al. AAV-mediated gene therapy halts retinal degeneration in PDE6beta-deficientDogs. Mol Ther 2016; 24: 867\u2013876.","journal-title":"Mol Ther"},{"key":"BFcgt201712_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1073858414521870","volume":"21","author":"DS Ojala","year":"2015","unstructured":"Ojala DS, Amara DP, Schaffer DV . Adeno-associated virus vectors and neurological gene therapy. Neuroscientist 2015; 21: 84\u201398.","journal-title":"Neuroscientist"},{"key":"BFcgt201712_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N . Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther 2016; 27: 478\u2013496.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201712_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","volume":"20","author":"DE Bowles","year":"2012","unstructured":"Bowles DE, McPhee SW, Li CW, Gray SJ, Samulski JJ, Camp AS et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20: 443\u2013455.","journal-title":"Mol Ther"},{"key":"BFcgt201712_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/73464","volume":"24","author":"MA Kay","year":"2000","unstructured":"Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257\u2013261.","journal-title":"Nat Genet"},{"key":"BFcgt201712_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342\u2013347.","journal-title":"Nat Med"},{"key":"BFcgt201712_CR18","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994\u20132004.","journal-title":"N Engl J Med"},{"key":"BFcgt201712_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","volume":"240","author":"JL Santiago-Ortiz","year":"2016","unstructured":"Santiago-Ortiz JL, Schaffer DV . Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release 2016; 240: 287\u2013301.","journal-title":"J Control Release"},{"key":"BFcgt201712_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gt.2012.43","volume":"20","author":"D Gaudet","year":"2013","unstructured":"Gaudet D, M\u00e9thot J, D\u00e9ry S, Brisson D, Essiembre C, Tremblay G et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013; 20: 361\u2013369.","journal-title":"Gene Ther"},{"key":"BFcgt201712_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/humc.2015.009","volume":"26","author":"L Bevaart","year":"2015","unstructured":"Bevaart L, Aalbers CJ, Vierboom MP, Broekstra N, Kondova I, Breedveld E et al. Safety, biodistribution, and efficacy of an AAV-5 vector encoding human interferon-beta (ART-I02) delivered via intra-articular injection in rhesus monkeys with collagen-induced arthritis. Hum Gene Ther Clin Dev 2015; 26: 103\u2013112.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"BFcgt201712_CR22","doi-asserted-by":"publisher","first-page":"22404","DOI":"10.1038\/srep22404","volume":"6","author":"XC Ma","year":"2016","unstructured":"Ma XC, Liu P, Zhang XL, Jiang WH, Jia M, Wang CX et al. Intranasal delivery of recombinant AAV containing BDNF fused with HA2TAT: a potential promising therapy strategy for major depressive disorder. Sci Rep 2016; 6: 22404.","journal-title":"Sci Rep"},{"key":"BFcgt201712_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.stem.2016.05.005","volume":"18","author":"M Rezvani","year":"2016","unstructured":"Rezvani M, Espa\u00f1ol-Su\u00f1er R, Malato Y, Dumont L, Grimm AA, Kienle E et al. In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis. Cell Stem Cell 2016; 18: 809\u2013816.","journal-title":"Cell Stem Cell"},{"key":"BFcgt201712_CR24","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/mt.2012.194","volume":"20","author":"S Yl\u00e4-Herttuala","year":"2012","unstructured":"Yl\u00e4-Herttuala S . Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012; 20: 1831\u20131832.","journal-title":"Mol Ther"},{"key":"BFcgt201712_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ijc.20982","volume":"116","author":"H Ma","year":"2005","unstructured":"Ma H, Liu YX, Liu SL, Kung HF, Sun XY, Zheng DX et al. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 2005; 116: 314\u2013321.","journal-title":"Int J Cancer"},{"key":"BFcgt201712_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/hep.20918","volume":"42","author":"H Ma","year":"2005","unstructured":"Ma H, Liu YX, Liu SL, Xu RA, Zheng DX . Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005; 42: 1355\u20131363.","journal-title":"Hepatology"},{"key":"BFcgt201712_CR27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/0008-5472.CAN-04-2749","volume":"65","author":"J Shi","year":"2005","unstructured":"Shi J, Zheng DX, Liu YX, Sham MH, Tam P, Farzaneh F et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687\u20131692.","journal-title":"Cancer Res"},{"key":"BFcgt201712_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","volume":"24","author":"L Lisowski","year":"2015","unstructured":"Lisowski L, Tay SS, Alexander IE . Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol 2015; 24: 59\u201367.","journal-title":"Curr Opin Pharmacol"},{"key":"BFcgt201712_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","volume":"14","author":"HY Jiang","year":"2006","unstructured":"Jiang HY, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, Smith P et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006; 14: 452\u2013455.","journal-title":"Mol Ther"},{"key":"BFcgt201712_CR30","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 2015; 372: 1887\u20131897.","journal-title":"N Engl J Med"},{"key":"BFcgt201712_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012; 23: 377\u2013381.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201712_CR32","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357\u20132365.","journal-title":"N Engl J Med"},{"key":"BFcgt201712_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ana.21732","volume":"66","author":"JR Mendell","year":"2009","unstructured":"Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G et al. Limb-girdle muscular dystrophy type 2D gene therapy restores \u03b1-sarcoglycan and associated proteins. Ann Neurol 2009; 66: 290\u2013297.","journal-title":"Ann Neurol"},{"key":"BFcgt201712_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/jgm.832","volume":"8","author":"J Yoo","year":"2006","unstructured":"Yoo J, Choi S, Hwang KS, Cho WK, Jung CR, Kwon ST et al. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J Gene Med 2006; 8: 163\u2013174.","journal-title":"J Gene Med"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201712","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cgt.2017.12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:09:57Z","timestamp":1647954597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFcgt201712"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2017.12","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]},"assertion":[{"value":"2 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}